Healthcare Startups Are Reshaping Wellness. Where Is the Industry Going?

U.S. digital health startups raised $14.2 billion in 2025, a 35% jump from the $10.5 billion raised in 2024 and the highest total since 2022, according to Rock Health. Yet the number of deals fell, from 509 to 482. More money went to fewer companies, and that single contrast explains much of what is happening in the sector.

Software engineers, physicians, biologists, and consumer brand builders now compete in the same market. A startup might sell an AI tool that drafts clinical notes or a wearable that tracks sleep. It might run a virtual clinic for menopause care or a platform that lets employers buy therapy sessions. All of them describe themselves as healthcare startups.

That shared label hides huge differences in risk, regulation, and evidence. A meditation app and a company building an FDA-regulated diagnostic have almost nothing in common except the word “health.” Understanding the landscape starts with seeing how many businesses sit under the label, and which of them are actually changing how care and wellness work.

The Market in Numbers

Funding data is the clearest window into where investors see opportunity. The table below uses figures from Rock Health’s reporting on U.S. digital health venture funding.

Several details sharpen the picture:

• Mega deals dominate. Rounds above $100 million made up 42% of 2025 funding, the highest share since 2021. There were 26 nine-figure raises in 2025, up from 18 in 2024.
• The average deal grew. The average round reached $29.3 million in 2025, compared with $20.7 million in 2024.
• AI carries a premium. AI-enabled companies commanded roughly a 19% higher average deal size, and the gap reached 61% at Series C.
• The middle is thinning. Only 30 Series B rounds closed through the third quarter of 2025, compared with an average of 63 a year over the prior three years. About 35% of rounds that year carried no series label at all, which makes it harder to judge which companies are ready to scale.
• Exits are picking up. Digital health M&A rose 61% to 195 deals in 2025, and five digital health companies went public.

What does it mean? Investors are placing large bets on a small group of perceived winners, especially in AI, while early and mid-stage companies face a tougher path. For founders, the lesson is that capital is abundant for companies with clear traction and scarce for everyone else.

The New Healthcare Startup Map

The sector is easier to understand by segment, because each one faces different customers, regulators, and economics.

The segments also differ in speed. A wellness app can launch in months. A diagnostic or therapeutic can take years and tens of millions of dollars of validation before it earns a dollar. That gap shapes who funds each category and how long investors must wait.

Why Investors and Founders Keep Coming

Healthcare attracts entrepreneurs for reasons that are partly financial and partly practical. Each driver below comes with a number that explains its pull.

Enormous spending. U.S. national health spending reached $5.3 trillion in 2024, or $15,474 per person, and accounted for 18% of GDP, according to CMS actuaries. That is up from $74.1 billion in 1970, when per person spending was $353, according to the Peterson-KFF Health System Tracker. CMS projects spending will approach $9 trillion by 2034, or 20.6% of the economy. Even small efficiency gains are worth billions.

Chronic disease. The CDC reports that six in ten U.S. adults have at least one chronic disease and four in ten have two or more. About 90% of health spending goes to people with chronic and mental health conditions. Adults with five or more chronic conditions spend about 14 times more on health services than adults with none, according to America’s Health Rankings. Startups that help manage chronic illness are aiming at the biggest cost center.

Unmet access. USAFacts, citing HRSA data, reported that an estimated 122 million Americans, about 37% of the population, live in mental health professional shortage areas. Two-thirds of those areas are rural or partly rural. Virtual care and digital tools are natural responses to shortages that training pipelines cannot fix quickly.

Administrative burden. An AMA survey found that 57% of physicians see automating administrative tasks as the biggest opportunity for AI. Documentation is a measurable problem that software can address.

Digitized data. Electronic records, wearables, and connected devices generate information that did not exist a generation ago, which makes analytics and AI possible.

Aging population. Older adults use more care and want to stay at home. That favors home monitoring, remote care, and coordination services.

Consumer demand. People are used to booking, tracking, and paying digitally, and they expect healthcare to follow.

The common thread is a system that is costly, complex, and growing. Startups see inefficiency, and investors see a market that keeps expanding.

Where the Money Is Going

Rock Health’s data shows how funding is distributed across categories and what it signals.

AI and workflow tools lead. AI-enabled companies took 54% of 2025 funding, and tools for clinical and non-clinical workflows together captured about 39%. These include documentation, coding, revenue cycle, and operations. The pattern suggests investors prefer products that save time for health systems over products that require patients to change behavior.

Fitness and wellness moved into the top tier. Rock Health noted that the category rose into the top tier of funded segments in 2025. Wearables, interest in preventive care and longevity, and renewed experiments with consumer-facing models drove the shift.

Other active areas include:

• Mental health, where employer-sponsored platforms such as Spring Health and Headway attracted valuations above $2 billion in 2024.
• Women’s health, covering fertility, pregnancy, and menopause, with companies like Maven Clinic and Pomelo Care, which raised $92 million to expand into women’s health and pediatric care.
• Remote care, including hospital-at-home and chronic condition platforms.
• Preventive health, such as lab testing memberships and longevity clinics.
• Personalized nutrition and metabolic health.
• Aging services, from home monitoring to care coordination.

Funding figures change quickly and are revised, so any number should be checked against current reports before it is quoted.

Companies and Startups Reshaping Wellness

Examples make the categories concrete. The companies below illustrate different business models, and their inclusion is not an endorsement. Valuations and funding figures are point-in-time and come from company announcements or press reports.

What the Examples Show

Employer and payer channels matter.

Hinge Health, Omada, Spring Health, and Maven sell mainly to employers and health plans rather than to individual patients. That route solves the “who pays” problem, though it ties revenue to a small number of large customers. Spring Health reported that more than 10 million people have access to its services through employers and health plans.

AI documentation is the clearest adoption story.

Physician use of AI rose from 38% in 2023 to 66% in 2024, according to the American Medical Association. The group called the jump unusually fast for healthcare technology. At Kaiser Permanente, 7,260 physicians used AI scribes in more than 2.5 million patient encounters over 14 months ending in December 2024, according to an analysis in NEJM Catalyst. Abridge and Ambience compete in a field where the product targets a measurable pain point. The test ahead is pricing pressure and switching costs.

Consumer wellness can scale fast.

Oura reported revenue above $500 million in 2024 and expected about $1 billion in 2025, according to CNBC’s coverage of its funding round. About 5.5 million rings had been sold by September 2025. Dexcom invested in Oura to support glucose monitoring integration, a sign that wellness hardware is moving toward metabolic health. Reports in 2026 indicate that Oura has been moving toward a public listing, so its current status should be verified.

The wellness and healthcare line can blur.

Function Health describes itself as a platform that connects consumers with existing laboratory services. It states that it does not provide medical advice, diagnosis, or treatment. That framing keeps it on the wellness side of the line even though lab results feel clinical. Patients benefit from asking who reviews the results and what happens if something looks abnormal.

Regulatory approval does not guarantee a business.

Pear Therapeutics was the first company to win FDA authorization for a prescription digital therapeutic. It still filed for bankruptcy in 2023, which underlines how important reimbursement and adoption are.

Company Profiles: The Startups and Companies in Detail

The table above summarizes twelve companies. The profiles below describe what each one builds and sells, who pays for it, and what to keep in mind. Figures come from company filings, company announcements, and press coverage, and many outcome claims are company-reported. They carry the date of their source, and they should be rechecked before publication.

Hinge Health

Hinge Health, founded in 2014, delivers digital care for back, knee, hip, and shoulder pain, along with post-surgical rehabilitation. After a member completes an intake questionnaire, the app generates an exercise plan. It uses the phone camera and computer vision, which the company calls TrueMotion, to check form and capture joint angles. Members can message a care team of physical therapists, physicians, and health coaches, and an AI assistant named Robin answers questions around the clock. The company also sells Enso, an FDA-cleared wearable device that delivers electrical nerve stimulation for pain.

Hinge sells to employers and health plans rather than to individuals. It reported 532,000 members and 20 million contracted lives at the end of 2024, and more than 2,250 enterprise customers when it filed to go public. Revenue for the 12 months ended March 31, 2025 was $432 million, and the company reported net income of $17.1 million in the first quarter of 2025. Access depends on whether an employer or plan contracts with Hinge, and much of the published outcome evidence comes from the company itself.

Omada Health

Omada, founded in 2011, runs virtual programs for diabetes, prediabetes, obesity, and high blood pressure. Members receive connected devices such as a scale or blood pressure cuff, plus coaching from a care team. AI tools summarize member data so that clinicians can decide on next steps. In 2023 the company launched its GLP-1 Care Track, which pairs prescribing support with lifestyle coaching for people taking GLP-1 medicines. Omada said the program had supported more than 150,000 members by the end of 2025. It has expanded distribution through the three leading pharmacy benefit managers and a partnership with Eli Lilly.

The business is growing fast. Omada reported 1.02 million members at the end of the first quarter of 2026, up 51% from a year earlier, and quarterly revenue of $78 million, up 42%. It guided to 2026 revenue of $322 million to $330 million. The company also reported an analysis in which GLP-1 Care Track members lost about 1.8 times as much weight as a control group over 12 weeks while preserving lean muscle. That analysis was run by the company and covers a short period, so independent and longer-term data would add confidence.

Abridge

Abridge builds ambient AI for clinical documentation. With patient consent, the software listens to a visit and drafts a structured note that the clinician reviews and signs, saving the time that used to be spent typing. It works inside the Epic electronic health record, including Epic’s mobile and desktop tools, and also integrates with Oracle Health and athenahealth. Vendor reviews describe coverage of more than 55 specialties and a feature that links statements in a note back to the source audio so that clinicians can verify them.

The company sells to large health systems and does not offer plans for individual clinicians. Reported customers include Mayo Clinic, Duke Health, Johns Hopkins, and Kaiser Permanente. Review coverage says it was named Best in KLAS for ambient AI in 2025 and 2026. Abridge raised a $300 million Series E in 2025 at a reported $5.3 billion valuation. Like every ambient scribe, it can make mistakes, which is why clinician review of each note remains part of the workflow.

Ambience Healthcare

Ambience offers an AI platform for documentation and coding. Its AutoScribe product captures the visit conversation and drafts the note, and the company tunes it to more than 200 specialties. Companion tools handle coding and clinical documentation improvement, after-visit summaries, referral letters, and pre-visit chart preparation. The platform integrates with Epic and Oracle Health, and reviews say it reads context from the chart as well as the conversation.

Where Abridge emphasizes breadth of deployment, Ambience emphasizes the financial side of documentation, such as coding accuracy and revenue integrity, and it works closely with customers on implementation. It reported a $243 million Series C at a valuation of about $1 billion. Pricing is typically negotiated with enterprise customers, and published comparisons of the two companies mostly come from vendors and review sites, so health systems usually run their own pilots.

Spring Health

Spring Health, founded in 2016, provides mental health benefits through employers and health plans. Members complete an assessment. The company’s Precision Mental Healthcare approach then uses data and machine learning to match each person to a level of care. Options range from self-guided tools and coaching to therapy and medication management. In January 2026, Spring Health announced an agreement to acquire Alma, a platform that helps independent clinicians run practices, and the deal closed on May 1, 2026.

Reach claims need careful reading. Spring Health says more than 170 million people worldwide have access to its services through employers, health plans, and partners. Independent reviews have described roughly 10 million members at 800 or more employers. Access and active membership are different measures. The company cites validation from JAMA Network Open and the Validation Institute, and it was valued at $3.3 billion after a $100 million round in July 2024. Rural availability of in-person care is more limited than in cities.

Headway

Headway solves a specific problem: many therapists do not accept insurance because credentialing and billing are burdensome. Headway builds a national network of therapists who do, and it handles credentialing, claims, and other paperwork for them. Patients search for a therapist who accepts their plan, book through the platform, and typically pay their normal copay. According to profile coverage, patients and therapists use the service for free, and Headway earns an administrative fee from insurers.

The model targets cost and access. By making insurance acceptance easier, Headway aims to bring therapy within reach of people who cannot afford self-pay rates. It reported a $100 million Series D at a $2.3 billion valuation in 2024. Availability varies by state and plan, wait times differ by location and clinician, and patients should confirm coverage before booking.

Maven Clinic

Maven operates a virtual clinic for women’s and family health. Members can message and video chat with more than 30 types of specialists, including OB-GYNs, midwives, doulas, lactation consultants, pediatricians, mental health providers, and nutritionists. Programs cover fertility, pregnancy, postpartum, parenting, and menopause. Employers or health plans typically pay for the service, so members use it at no cost.

Maven publishes outcome claims, such as 30% of fertility members achieving pregnancy without assisted reproductive technology and up to 27% lower NICU admissions among some members. These figures are company-reported and depend on the population served. Maven has also announced a partnership with Goldman Sachs to expand family-building and menopause benefits, and industry observers often list it as a possible IPO candidate. Individuals cannot usually sign up on their own, since access depends on the employer or plan.

Oura

Oura, a Finnish company, makes a smart ring that tracks sleep, heart rate, heart rate variability, skin temperature, and activity. The Ring 4, launched in October 2024, feeds an app that produces daily readiness and sleep scores and long-term trends, with women’s health and cycle features. A partnership with Dexcom connects glucose data to the app so that users can see how food relates to metabolic health. The ring has a one-time cost plus a membership, with a reported price of $5.99 a month in early 2026 reviews.

Oura’s scale is notable. The company reported revenue above $500 million in 2024 and expected about $1 billion in 2025, according to CNBC. It raised about $900 million at a valuation near $11 billion in October 2025. About 5.5 million rings had been sold by September 2025. Oura is a wellness product. Its scores are proprietary, and its features are not diagnostic.

Function Health

Function Health sells a membership that coordinates blood testing. Members get access to more than 100 biomarkers, and later reviews cite 160 or more. Blood draws happen at Quest Diagnostics sites, and results appear in an app with clinician-written commentary. In May 2025, Function acquired Ezra, a full-body MRI company that uses FDA-cleared AI to shorten scan times to about 22 minutes. It later added a heart CT scan. Reports say it bought the at-home testing company Getlabs in April 2026 and the supplement-testing platform SuppCo in May 2026.

Pricing has moved, with sources reporting a $499 annual membership at launch and $365 in early 2026 reviews, so current terms should be checked. Function raised a $298 million Series B at a $2.5 billion valuation in November 2025, and reports describe an additional $450 million from General Catalyst in July 2026. The company states that it is not a laboratory or medical provider. Imaging for healthy people is contested. Radiology groups have cautioned that evidence is lacking that whole-body MRI screening of people without symptoms improves outcomes. Extra findings can also lead to further testing.

Sword Health

Sword Health provides digital physical therapy that competes with Hinge. Its Thrive program treats joint and muscle pain using motion sensors or camera-based tracking, and its Bloom program covers pelvic and women’s health. In 2025 the company added Mind, a mental health program. Its AI care specialist, called Phoenix, interacts with members and is supervised by licensed clinicians. Like Hinge, Sword sells mainly to self-insured employers and health plans, often with outcome-based pricing.

Sword reported a $40 million round at a $4 billion valuation in June 2025, and industry commentary often names it as a possible public listing candidate. Outcome and savings claims come mainly from the company and its customers, so buyers typically look for independent validation. For individuals, availability depends on whether an employer or plan has a contract.

Tempus AI

Tempus, led by founder Eric Lefkofsky, combines genomic testing with AI and a large clinical data library to support precision medicine, mainly in cancer. Its tumor profiling test, xT CDx, received a Medicare ADLT price of $4,500 per test, and its hereditary testing arm came from the February 2025 acquisition of Ambry Genetics. The company also sells data licensing and analytics to drug developers. AI products include Paige, a digital pathology business bought in August 2025 that holds nearly seven million slide images. Paige Predict analyzes standard slides to predict 123 biomarkers across 16 cancer types. FDA-cleared tools include cardiac imaging software and an ECG algorithm that flags low ejection fraction.

Tempus listed on Nasdaq in June 2024 and reported 2025 revenue of $1.27 billion, up 83.4%, including $955 million from diagnostics and $316 million from data and applications. Adjusted EBITDA came close to break-even in the fourth quarter, though the company still reported net losses, including $80 million in the third quarter of 2025. Part of the growth came from acquisitions such as Ambry, so organic growth is lower than the headline figure.

Pear Therapeutics

Pear, based in Boston, pioneered prescription digital therapeutics. Its reSET product, authorized by the FDA in 2017, delivers cognitive behavioral therapy through an app for people with substance use disorder, used alongside outpatient treatment. reSET-O followed for opioid use disorder, and Somryst delivered cognitive behavioral therapy for chronic insomnia. Clinicians prescribed these products, which was a different model from consumer wellness apps.

The company went public in 2021 and filed for bankruptcy in 2023, and its products were later sold to other companies. Regulatory authorization had not translated into reliable reimbursement or clinician adoption. Pear remains the standard example of a point made throughout this article: an evidence-backed product still needs a payer, a workflow that fits, and a customer who renews.

Wellness Versus Healthcare

The regulatory line depends on claims. A product that supports general wellness, such as step counting or stress reduction, generally faces little FDA oversight. A product that claims to diagnose, treat, or prevent a disease may be a medical device or even a drug.

Many startups begin in wellness for speed, then try to move toward clinical claims as they gather evidence. Oura illustrates the path: a consumer ring that now partners with a glucose monitoring company and markets heart and women’s health features. Each added claim raises the evidence bar.

The distinction matters to patients because wellness products can feel clinical. A dashboard of lab results or a risk score looks authoritative, but the company may carry no obligation to validate it the way a regulated device must.

What Makes a Healthcare Startup Credible

Credibility is not a single feature. It is a set of signals that reinforce one another.

• Clinical evidence. Published studies, preferably independent and peer reviewed. Company-commissioned analyses count for less. Spring Health, for example, cited a Validation Institute review that reported health plan savings of $2,430 per participant in the first six months. Third-party validation helps, but readers should still ask who commissioned the work and how long outcomes were tracked.
• Qualified leadership. Clinicians, scientists, and operators with relevant experience reduce the risk of well-meaning mistakes.
• A regulatory pathway. A clear plan for FDA or state requirements shows the company understands its obligations.
• Data security. Compliance with HIPAA where relevant, and strong cybersecurity, matter because health data is both sensitive and valuable.
• Reimbursement strategy. A plan for who pays determines whether the product reaches patients at scale.
• A sound business model. Revenue that does not depend on endless funding.
• Patient outcomes. Measured results, not just user numbers.

The difference between a company claim and an independently validated outcome is crucial. A press release stating that users “improved” is not the same as a controlled study.

Why Many Startups Struggle

Healthcare punishes shortcuts. Each obstacle below has shaped real outcomes.

• Long sales cycles. Hospitals and insurers can take a year or more to buy, which strains young companies that burn cash.
• Regulatory requirements. Compliance takes time and money. The FDA has authorized more than 1,600 AI-enabled devices as of September 2026, mostly in radiology, which shows how heavily the field is regulated and how long clearances take.
• Validation costs. Clinical studies are expensive, and they must run long enough to show lasting outcomes.
• Provider adoption. Tools that add clinician work get ignored. The AMA found that 84% of physicians said successful AI adoption requires seamless integration with electronic health records.
• Reimbursement. Without a payer, patients may not use the product, and employers want proof of savings.
• Interoperability. Connecting to electronic health records is hard, and data trapped in separate systems limits usefulness.
• Trust. Patients and clinicians need reasons to believe. In the same AMA survey, 47% said more FDA oversight of AI-enabled devices would increase their trust.
• Valuation resets. Hinge Health priced its 2025 IPO at about $2.6 billion, well below the $6.2 billion private valuation it held in late 2021. Even strong companies had to accept lower marks.

Pear Therapeutics shows how these forces combine. It won FDA authorization for the first prescription digital therapeutic in 2017, yet it filed for bankruptcy in 2023 after struggling to secure reimbursement and adoption. Approval alone does not create a business.

How Startups Make Money

Business models shape incentives, and incentives shape behavior. Patients and clinicians benefit from knowing who actually pays.

Companies that depend on one payer or one policy decision carry more risk. A change in reimbursement rules can alter the economics overnight. Medicare accounted for 21% of national health spending in 2024, and the federal government sponsored 31%, which shows why policy decisions in Washington can reshape a startup’s market.

The Startup Models Likely to Matter Most

Not every model will last. These are the ones with the strongest connection to measurable problems.

• Provider enablement. Tools that reduce paperwork and let clinicians see more patients. Documentation and revenue cycle products captured the largest share of 2025 funding, and the AMA found that about one in five physicians used AI for documentation in 2024.
• Home care technology, supporting hospital-at-home and aging in place, as older adults prefer to stay in their homes.
• AI clinical support, especially documentation and imaging, where regulators and trials provide a path to evidence.
• Remote monitoring, where reimbursement exists. Medicare telehealth flexibilities run through December 31, 2027, which gives the segment a stable runway.
• Preventive health, if outcomes and cost savings are proven. Chronic disease drives 90% of spending, so prevention that works would be valuable, but proof takes years.
• Consumer wellness, which will remain large but harder to differentiate as wearables become common.

The pattern is that startups tied to clear workflow problems and payers tend to last longer than those chasing attention.

A Regulatory Snapshot

Regulation affects timelines and costs more than most founders expect. A product that makes a medical claim may go through one of several FDA pathways. The 510(k) route compares a device with an existing one, the De Novo route covers novel lower-risk devices, and premarket approval applies to the highest-risk products. Software that meets the definition of a medical device follows these routes just as hardware does.

Other rules apply too. HIPAA governs how covered entities and their partners handle health data. States license clinicians and set telehealth rules, so a virtual clinic must comply with each state where it treats patients. The FTC polices deceptive health claims and data practices. Founders who build these requirements into the plan early usually move faster than those who add them later.

In Depth: What the 2025 IPOs Reveal About Which Startups Win

Public markets offer one of the clearest tests of whether a healthcare startup has a real business. After a drought that followed the 2021 boom, a small group of digital health companies listed in 2025, and their results show what investors rewarded.

The Drought and the Reopening

Many digital health companies went public in 2021 amid record venture funding. Several performed poorly, and the IPO window largely closed until 2025. Hinge Health reopened it on May 22, 2025. It priced at $32 per share, the top of its range, and raised about $437 million. Shares opened 23% higher on the first day. Omada Health followed in early June, pricing at $19 and raising about $150 million.

Both listings carried a lesson about valuation. Hinge’s roughly $2.6 billion IPO valuation was well below its $6.2 billion private valuation in late 2021. Omada’s roughly $1.1 billion valuation was close to its 2022 private mark, so it avoided a sharp down round.

What Investors Valued

Analysts at Bessemer Venture Partners compared the two companies in their 2026 health tech review. The figures below reflect that analysis and change with the market.

Hinge’s combination of fast growth and strong cash generation earned a higher multiple. Omada grew quickly but was roughly break even on cash. The market paid more for operating discipline than for growth alone.

Common Traits of the Winners

• A clear buyer. Both sell to employers and health plans that pay for a defined service.
• A defined clinical focus. Musculoskeletal pain, diabetes, obesity, and hypertension are costly, common conditions with measurable outcomes.
• Scale and discipline. These were mature companies with years of revenue, not early-stage ideas.
• Transparency. Public company status requires SEC filings, which let outsiders examine revenue, customer concentration, and risks.

The Window Narrows Again

The reopening did not become a flood. According to one industry review, no core digital health platform completed an IPO in the first half of 2026, even as biotechnology and other healthcare sectors accessed public capital. Rock Health’s data on private funding points the same way: capital is concentrating, with 19 companies raising 45% of the $7.4 billion invested in the first half of 2026.

The implication is that investors favor a small number of proven leaders. Early-stage companies without a payer, clinical evidence, or a path to profit face a harder environment.

What This Means for Patients and Partners

Public filings offer a useful resource. A company’s annual report describes its customers, its risks, and the evidence it cites for outcomes. Patients and employers evaluating a service can read the risk factors section to see what the company itself says could go wrong. A strong valuation is not a measure of clinical quality, and a startup that is private will not offer the same transparency. The practical step is the same as elsewhere in this article: look for independent evidence of results, not just growth.

Signals to Watch in 2027

Several developments will shape which startups succeed. Each one is worth tracking because it changes economics, not just headlines.

• Reimbursement decisions for remote monitoring and digital therapeutics. Payment is the difference between a pilot and a business.
• FDA clearances and how regulators handle adaptive and generative AI. As of March 2026, trade analysts noted that no authorized device was powered by a large language model. The first such clearances will be closely watched.
• Consolidation. M&A volume rose 61% in 2025, and larger health systems, insurers, and technology firms are acquiring smaller companies to add capabilities.
• Evidence from real use, especially independent studies of outcomes and cost.
• Privacy enforcement, as regulators scrutinize health data handling.
• Telehealth policy, since Medicare flexibilities currently run through December 31, 2027, which makes the next legislative decision important.
• The IPO window. Whether scaled companies such as Abridge or Oura reach public markets will show whether 2025 was a one-time reopening or a lasting trend.

How Patients Should Evaluate a Startup

1. Evidence. Search for published studies on the specific product, and note who funded them.
2. Privacy. Read how health data is stored and shared, and whether the service falls under HIPAA.
3. Credentials. Check that licensed clinicians are involved in care.
4. Regulatory status. Look up FDA listings for device claims.
5. Pricing. Understand fees, subscriptions, and what insurance covers.
6. Clinical oversight. Confirm how problems and emergencies are handled.

Trying a new service is not risky in itself. The risk grows when a company promises results that outpace its evidence.

A Short Checklist for Partners and Investors

Beyond patients, hospitals and employers also evaluate startups. A reasonable checklist asks four things. Can the company show independently validated results? Do customers renew after pilots? Does the team include experienced clinicians? Does revenue rely on a payer that has agreed to pay? Pilots that never convert to contracts are a common warning sign.

What Failures Teach

Several well-publicized failures share a pattern. The technology worked, or appeared to. Then the company lacked a durable path to payment, clinicians did not adopt it, or growth required spending that investors would not keep funding. The lesson is not that digital health cannot succeed. It is that evidence, workflow fit, and a payer willing to pay all have to line up.

Patients and clinicians can also watch how a company talks about its own limits. Startups that publish their evidence, name their clinical advisers, and explain what the product should not be used for tend to inspire more trust than those that promise broad results.

Where the Strongest Stories Come From

The most durable healthcare innovation combines technical capability with clinical usefulness. A product that is clever but unneeded fades. A product that solves a real problem, shows outcomes, and fits how care is paid for can scale.

The numbers suggest an industry in transition. Funding is rising but concentrating. Physician adoption of AI is moving faster than almost any prior technology. Public markets reward discipline over growth alone. The field will keep producing both breakthroughs and failures, and patients, clinicians, and investors benefit from asking the same question: what evidence shows this works, and for whom?

Health information disclaimer: This content is for general information only and is not medical, legal, or investment advice. Funding figures and company details change frequently. Verify current information before relying on it.

FAQ

Q: What is a healthcare startup?

A: A young company building products or services in health, from software and devices to biotech and virtual care.

Q: How much funding do healthcare startups raise?

A: U.S. digital health startups raised $14.2 billion in 2025 across 482 deals, according to Rock Health, and $7.4 billion in the first half of 2026.

Q: What are the biggest healthcare startup sectors?

A: AI, mental health, remote care, preventive health, women’s health, fitness and wellness, and aging services draw significant attention and funding.

Q: What makes a health startup successful?

A: Solving a real clinical or operational problem, showing outcomes, meeting regulatory requirements, and securing reimbursement or a paying customer.

Q: How are healthcare startups regulated?

A: It depends on the product. Medical devices and diagnostics may need FDA authorization, telehealth faces state rules, and health data is subject to privacy laws.

Q: What is the difference between wellness and digital health?

A: Wellness supports general health and faces light oversight. Digital health that makes medical claims faces medical regulation.

Q: Are healthcare startups safe?

A: Safety varies. Look for clinical evidence, clinician involvement, privacy protections, and clear regulatory status.

Q: Why do so many healthcare startups fail?

A: Long sales cycles, regulatory costs, reimbursement gaps, and poor integration with clinicians’ workflows.

Q: Why is AI attracting so much healthcare funding?

A: AI companies took 54% of 2025 digital health funding, driven by products that reduce administrative work, such as clinical documentation.